HUMAN PROTEIN TYROSINE PHOSPHATASE BETA BINDING ANTIBODIES (HPTPBETA), AND USE THEREOF Russian patent published in 2013 - IPC C07K16/40 A61K39/395 A61P43/00 A61P35/00 A61P37/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention describes methods of treating an angiogenesis regulated disorder, involving the administration of an effective amount of the human protein tyrosine phosphatase beta (HPTPβ) binding antibody to an individual. Binding the antibody to HPTPβ improves Tie-2 signal transmission and thereby regulates (increases or decrease) angiogenesis depending on the disease. The used antibody is produced by the hybridoma ATCC №PTA-7580. The antibody provides a basis to prepare a pharmaceutical composition for treating the angiogenesis regulated disease which contains both the antibody, and a pharmaceutically acceptable carrier.

EFFECT: methods according to the invention are used to treat the disorders accompanied by decreased or increased angiogenesis, particularly the diseases such as musculoskeletal or myocardial ischemia, stroke, coronary artery and peripheral vascular disease, sickle-cell anaemia, Paget disease, Lyme disease and others.

7 cl, 12 dwg, 1 tbl, 6 ex